A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer

Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]

Prostvac In Combination With Yervoy Yields A Survival Advantage

There is some really exciting news on the horizon around immunotherapy for advanced prostate cancer. Bavarian Nordic, the pharmaseutical company that has, along with the National Cancer Institute (NCI), been running clinical trials on Prostvac has unoffically let it been known that Prostvac when combined with another investigational immunologic therapy, Yervoy, has helped to significantly [...]

The Ipilimumab (Yervoy) Results – A Failure that Should Not Have Been A Failure

Last October at the European Cancer Congress 2013 there was a release of data from a phase 3 study of Ipilimumab (CA 184-043) that showed that it might be effective in treating castration-resistant prostate cancer in men who have a low burden of disease; however it failed to show at the required 95% confidence level [...]

Yervoy (ipilimumab) Fails to Extend Survival in Men with mCRP Who Failed Chemo

Some bad news was reported today. Results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in men with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel showed no increase in overall survival. Yervoy is an immunotherapy which [...]

Teleconference – A New PROSPECT for Prostate Cancer Patients this Tuesday at 6 p.m.

Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m. I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within [...]

The New Yorker Magazine Publishes A Great Article on Immunotherapy

For those who might be interested in the April 23, 2012 edition of The New Yorker Magazine, Jerome Groopman has written an excellent article on the history and current state of Immunotherapy. The article is entitled "The T-Cell Army" and it is on page 24. Not only does the article review the history (going all [...]

A Look at the Status of Cancer Vaccines – Emerging Treatments

From very early on, researchers and doctors have dreamed of using the body’s own immune system to fight cancer. The big question has been why doesn’t the immune system attack the tumor cells that invade healthy tissue? The really good news is that finally science is catching up with this vision. Therapeutic cancer vaccines that [...]